Pharmaceutical intermediates
Cangrelor Tetrasodium Intermediates
2 pharmaceutical intermediates for Cangrelor Tetrasodium. Indication: Coronary thrombosis; Myocardial infarction; Thrombosis; Acute coronary syndrome.
About Cangrelor Tetrasodium
- Originator
- The Medicines Company
- Indication
- Coronary thrombosis; Myocardial infarction; Thrombosis; Acute coronary syndrome
- Approved Date
- 06/22/2015
- DS/DP
- 05/13/2029
Available intermediates
2 intermediates currently listed for Cangrelor Tetrasodium. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (2R,3S,4R,5R)-2-(hydroxyMethyl)-5-(6-((2-(Methylthio)ethyl)aMino)-2-((3,3,3-trifluoropropyl)thio)-9H-purin-9-yl)tetrahydrofuran-3,4-diol | 163706-58-9 | / | / |
| Phosphonic acid, P,P'-(dichloromethylene)bis-, compd. with N,N-dibutyl-1-butanamine (1:1) | 163706-61-4 | / | / |
Building toward Cangrelor Tetrasodium?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →